Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
SLO
Login
Search
Browsing
Upload document
Statistics
RUP
FAMNIT - Faculty of Mathematics, Science and Information Technologies
FHŠ - Faculty of Humanities
FM - Faculty of Management
FTŠ Turistica - Turistica – College of Tourism Portorož
FVZ - Faculty of Health Sciences
IAM - Andrej Marušič Institute
PEF - Faculty of Education
UPR - University of Primorska
ZUP - University of Primorska Press
COBISS
University of Primorska, University Library - all departments
First page
/
Show document
Show document
A-
|
A+
|
Print
Title:
Tržni delež in prepoznavnost svetovalnega podjetja
Authors:
ID
Lipičar, Polona
(Author)
ID
Faganel, Armand
(Mentor)
More about this mentor...
Files:
http://www.ediplome.fm-kp.si/Lipicar_Polona_20090714.pdf
Lipicar_Polona_20090714.pdf
(367,41 KB)
MD5: 35228715852069C29BB91867B105B3E8
Language:
Slovenian
Work type:
Undergraduate thesis
Typology:
2.11 - Undergraduate Thesis
Organization:
FM - Faculty of Management
Keywords:
podjetništvo
,
svetovanje
,
tržni delež
,
sodobno trženje
,
storitve
Place of publishing:
Koper
Publisher:
[P. Lipičar]
Year of publishing:
2009
Number of pages:
VIII, 33 str. + pril.
PID:
20.500.12556/RUP-697
UDC:
659.235(043.2)
COBISS.SI-ID:
3171543
Publication date in RUP:
15.10.2013
Views:
12540
Downloads:
179
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
LIPIČAR, Polona, 2009,
Tržni delež in prepoznavnost svetovalnega podjetja
[online]. Bachelor’s thesis. Koper : P. Lipičar. [Accessed 29 March 2025]. Retrieved from: https://repozitorij.upr.si/IzpisGradiva.php?lang=eng&id=697
Copy citation
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:
Voting is allowed only for
logged in
users.
Share:
Similar works from our repository:
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN)
Trans-esophageal endobronchial ultrasound-guided needle aspiration (EUS-B-NA)
Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe
Similar works from other repositories:
Vpliv izražanja receptorja za inzulinu podoben rastni dejavnik 1 (IGF1R) na preživetje pri razsejanem nedrobnoceličnem raku pljuč
Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
Uporabnost imunohistokemičnega določanja mutacij receptorja za epidermalni rastni faktor pri raku pljuč
Sistematični pregled opazovalnih raziskav učinkovitosti in varnosti zaviralcev imunskih kontrolnih točk pri zdravljenju razsejanega nedrobnoceličnega raka pljuč
Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.
Comments
Leave comment
You must
log in
to leave a comment.
Comments (0)
0 - 0 / 0
There are no comments!
Back